Security key
52187K200
CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (CYPH)
CUSIP: 52187K200
Q2 2025 13F Holders as of 30 Jun 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 13,760,432
- Total 13F value
- $4,082,824
- Share change
- -2,932,747
- Put/Call ratio
- 285%
- SEC-reported price per share
- $0.30
- Number of holders
- 41
- Value change
- -$901,531
- Number of buys
- 16
- Number of sells
- 20
- Shares outstanding
- 60,725,945
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2025
Institutions
41
Top holders
10
CYPH full security history
Ownership snapshot
Full 13F holder table
CYPHERPUNK TECHNOLOGIES INC. SEC filings
CYPHERPUNK TECHNOLOGIES INC. company facts
Broader feeds
Ownership snapshot
Top reported holders of CYPH - CYPHERPUNK TECHNOLOGIES INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BeOne Medicines Ltd.
Disclosed value leader
BeOne Medicines Ltd.
Comparable rows
15/15
Latest evidence
31 Mar 2025
3/4/5
13D/G
13F
Lead comparable stake: 2%
13D/G row: BeOne Medicines Ltd.
Showing 1-6 of 15 holder rows.
Quick read
BeOne Medicines Ltd. leads the comparable SEC ownership view at 2%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BeOne Medicines Ltd.'s linked filing trail.
Comparable ownership
Top 5
BeOne Medicines Ltd.
2%
GILEAD SCIENCES, INC.
8.8%
Samsara BioCapital, LLC
4%
683 Capital Management, LLC
2.4%
ACADIAN ASSET MANAGEMENT LLC
2.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BeOne Medicines Ltd. |
3/4/5
13D/G
10%+ Owner · BeiGene, Ltd.
|
2%
from 13D/G
|
$20,943,045
7,348,437 shares
|
— | 24 Sep 2021 |
| GILEAD SCIENCES, INC. |
3/4/5
13F
10%+ Owner · Company
|
8.8%
from 13F
|
$15,159,572
5,319,148 shares
|
— | 10 Apr 2024 |
| Samsara BioCapital, LLC |
13F
Company
|
4%
|
$745,162
2,442,352 shares
|
— | 31 Mar 2025 |
| 683 Capital Management, LLC |
13F
Company
|
2.4%
|
$442,364
1,449,900 shares
|
— | 31 Mar 2025 |
| ACADIAN ASSET MANAGEMENT LLC |
13F
Company
|
2.1%
|
$389,000
1,280,531 shares
|
— | 31 Mar 2025 |
| VANGUARD GROUP INC |
13F
Company
|
1.9%
|
$358,558
1,175,598 shares
|
— | 31 Mar 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
41
Shares
13,760,432
Rows available
41
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
44
Q2 2025 holders
41
Holder diff
-3
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 value | Q2 2025 value | Value change | Value Chg % |
|---|